PluriStem Therapeutics Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by PluriStem Therapeutics Inc. on September 16, 2013. The registrant is a Nevada corporation headquartered in Haifa, Israel, focused on stem cell therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report addresses a specific regulatory event rather than financial performance.
Material Changes
The primary material event reported is the lifting of a clinical hold by the U.S. Food and Drug Administration (FDA). The hold, originally placed on June 4, 2013, concerned the company's U.S. Phase II study for Intermittent Claudication (IC) under Investigational New Drug (IND) application 15038.
Outlook and Management Commentary
Management announced the FDA's decision to lift the clinical hold on September 16, 2013. This action allows the company to proceed with its Phase II IC study. The filing does not contain specific forward-looking guidance, risk factors, or details on unusual items beyond this regulatory update.
Key Facts for Investor Verification
- The FDA lifted the clinical hold on the Phase II Intermittent Claudication study (IND 15038) on September 16, 2013.
- The clinical hold had been in effect since June 4, 2013.
- The report was signed by Yaky Yanay, Chief Financial Officer.
- No financial data or updated guidance is included in this specific filing.